{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:32Z","timestamp":1792079672431,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["UIP-2019-04-8277"],"award-info":[{"award-number":["UIP-2019-04-8277"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.coph.2024.102476","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:34:31Z","timestamp":1724376871000},"page":"102476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-0031","authenticated-orcid":false,"given":"Ivica","family":"Matak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko","family":"Lackovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2024.102476_sref1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00204-022-03271-9","article-title":"Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update","volume":"96","author":"Pirazzini","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.coph.2024.102476_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/toxins11080459","article-title":"Mechanisms of botulinum toxin type A action on pain","volume":"11","author":"Matak","year":"2019","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2024.102476_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","article-title":"Botulinum toxin treatment of pain syndromes -an evidence based review","volume":"147","author":"Safarpour","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.coph.2024.102476_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cre2.882","article-title":"Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: a systematic review","volume":"10","author":"Naderi","year":"2024","journal-title":"Clin Exp Dent Res"},{"key":"10.1016\/j.coph.2024.102476_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/toxins10050208","article-title":"The expanding therapeutic utility of botulinum neurotoxins","volume":"10","author":"Fonfria","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2024.102476_sref6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032378","article-title":"Botulinum neurotoxins: future innovations","volume":"102","author":"Brideau-Andersen","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.coph.2024.102476_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/13543784.13.11.1437","article-title":"The analgesic potential of clostridial neurotoxin derivatives","volume":"13","author":"Foster","year":"2004","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.coph.2024.102476_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/11534510-000000000-00000","article-title":"Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects","volume":"24","author":"Pickett","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.coph.2024.102476_bib9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.coph.2024.102476_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","article-title":"Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins","volume":"38","author":"Welch","year":"2000","journal-title":"Toxicon"},{"issue":"Suppl 8","key":"10.1016\/j.coph.2024.102476_bib11","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.20008","article-title":"Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in\u00a0vitro, and antinociceptive activity in in\u00a0vivo models of pain","volume":"19","author":"Chaddock","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.coph.2024.102476_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00702-004-0265-1","article-title":"Botulinum toxin type A in experimental neuropathic pain","volume":"112","author":"Bach-Rojecky","year":"2005","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.coph.2024.102476_bib13","first-page":"201","article-title":"Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain","volume":"46","author":"Bach-Rojecky","year":"2005","journal-title":"Croat Med J"},{"key":"10.1016\/j.coph.2024.102476_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1213\/ANE.0b013e3181ffa1d7","article-title":"Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice","volume":"112","author":"Lee","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/j.coph.2024.102476_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2006.01.117","article-title":"Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice","volume":"1082","author":"Luvisetto","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2024.102476_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","article-title":"Central origin of the antinociceptive action of botulinum toxin type A","volume":"94","author":"Bach-Rojecky","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.coph.2024.102476_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.06.040","article-title":"Involvement of substance P in the antinociceptive effect of botulinum toxin type A: evidence from knockout mice","volume":"358","author":"Matak","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2024.102476_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2024.102476_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.coph.2024.102476_bib33","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1526-4637.2009.00711.x","article-title":"Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis","volume":"10","author":"Krug","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.coph.2024.102476_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00702-012-0846-3","article-title":"Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats","volume":"120","author":"Matak","year":"2013","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.coph.2024.102476_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/toxins9090269","article-title":"Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum holoproteins (ciBoNT HPs) as vaccine candidates for the prevention of botulism","volume":"9","author":"Webb","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2024.102476_bib18","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.pain.2013.07.041","article-title":"Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A","volume":"154","author":"Mustafa","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.coph.2024.102476_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-021-00973-8","article-title":"Anthrax toxins regulate pain signaling and can deliver molecular cargoes into ANTXR2+ DRG sensory neurons","volume":"25","author":"Yang","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2024.102476_bib21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/bc4003103","article-title":"Synthetic self-assembling clostridial chimera for modulation of sensory functions","volume":"24","author":"Ferrari","year":"2013","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.coph.2024.102476_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7384","article-title":"Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice","volume":"10","author":"Maiar\u00f9","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2024.102476_bib36","article-title":"Substance P-botulinum mediates long-term silencing of pain pathways that can be Re-instated with a second injection of the construct in mice","volume":"25","author":"Maiar\u00f9","year":"2024","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.coph.2024.102476_bib20","doi-asserted-by":"crossref","first-page":"18197","DOI":"10.1073\/pnas.1007125107","article-title":"SNARE tagging allows stepwise assembly of a multimodular medicinal toxin","volume":"107","author":"Darios","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2024.102476_bib22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/j.pain.0000000000000478","article-title":"Nonparalytic botulinum molecules for the control of pain","volume":"157","author":"Mangione","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.coph.2024.102476_sref24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s13311-020-00967-7","article-title":"Double-binding botulinum molecule with reduced muscle paralysis: evaluation in in\u00a0vitro and in\u00a0vivo models of migraine","volume":"18","author":"Andreou","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.coph.2024.102476_sref26","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201631","article-title":"New botulinum neurotoxin constructs for treatment of chronic pain","volume":"6","author":"Leese","year":"2023","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.coph.2024.102476_bib28","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1074\/jbc.M110.181784","article-title":"A\u00a0dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic","volume":"286","author":"Wang","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2024.102476_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.03.026","article-title":"A\u00a0novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain","volume":"118","author":"Wang","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2024.102476_sref30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/toxins14020116","article-title":"Botulinum neurotoxin chimeras suppress stimulation by capsaicin of rat trigeminal sensory neurons in\u00a0vivo and in\u00a0vitro","volume":"14","author":"Antoniazzi","year":"2022","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2024.102476_bib27","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","volume":"29","author":"Meng","year":"2009","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.coph.2024.102476_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Zhang","year":"2014","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.coph.2024.102476_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.828427","article-title":"Cell-penetrating botulinum neurotoxin type A with improved cellular uptake and therapeutic index","volume":"10","author":"Wei","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.coph.2024.102476_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000245","article-title":"Botulinum neurotoxin devoid of receptor binding domain translocates active protease","volume":"4","author":"Fischer","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coph.2024.102476_bib40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/IAI.00063-15","article-title":"The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions","volume":"83","author":"Ayyar","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.coph.2024.102476_bib41","article-title":"Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2024.102476_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/BJ20131387","article-title":"Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X(3) inhibits the release of a pain mediator","volume":"462","author":"Ma","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.coph.2024.102476_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","article-title":"Botulinum toxin therapy, immunologic resistance, and problems with available materials","volume":"46","author":"Borodic","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2024.102476_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coph.2024.102476_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/srep30429","article-title":"Pre-clinical study of a novel recombinant botulinum neurotoxin derivative engineered for improved safety","volume":"6","author":"Vazquez-Cintron","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2024.102476_bib46","article-title":"Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring","volume":"63","author":"Eng","year":"2016","journal-title":"Dan Med J"},{"key":"10.1016\/j.coph.2024.102476_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1526-4637.2011.01164.x","article-title":"Spinal toxins can have persistent adverse effects","volume":"12","author":"Yaksh","year":"2011","journal-title":"Pain Med"},{"key":"10.1016\/j.coph.2024.102476_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24122","article-title":"Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction","volume":"75","author":"Paterson","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2024.102476_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2009.06.047","article-title":"Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models","volume":"617","author":"Favre-Guilmard","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2024.102476_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029803","article-title":"Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy","volume":"7","author":"Filipovi\u0107","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2024.102476_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176279","article-title":"Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis","volume":"963","author":"Nemani\u0107","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2024.102476_bib52","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.pain.2014.04.027","article-title":"Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons","volume":"155","author":"Matak","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.coph.2024.102476_bib53","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pain.2013.12.009","article-title":"Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior","volume":"155","author":"Marino","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.coph.2024.102476_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nbd.2015.04.011","article-title":"Botulinum toxin in migraine: role of transport in trigemino-somatic and trigemino-vascular afferents","volume":"79","author":"Ramachandran","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.coph.2024.102476_bib55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2013.02.011","article-title":"Involvement of \u03bc-opioid receptors in antinociceptive action of botulinum toxin type A","volume":"70","author":"Drinovac","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2024.102476_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00702-013-1150-6","article-title":"Association of antinociceptive action of botulinum toxin type A with GABA-A receptor","volume":"121","author":"Drinovac","year":"2014","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.coph.2024.102476_bib58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxicon.2017.02.010","article-title":"Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats","volume":"129","author":"Lora","year":"2017","journal-title":"Toxicon"},{"issue":"4 Pt 1","key":"10.1016\/j.coph.2024.102476_bib59","first-page":"1529","article-title":"Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats","volume":"172","author":"Chuang","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.coph.2024.102476_sref60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25002-x","article-title":"Intraoperative abobotulinumtoxinA alleviates pain after surgery and improves general wellness in a translational animal model","volume":"12","author":"Cornet","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2024.102476_sref61","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/toxins13110751","article-title":"Botulinum neurotoxins in central nervous system: an overview from animal models to human therapy","volume":"13","author":"Luvisetto","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.coph.2024.102476_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/toxins11020123","article-title":"Botulinum neurotoxin light chains expressed by defective herpes simplex virus type-1 vectors cleave SNARE proteins and inhibit CGRP release in rat sensory neurons","volume":"11","author":"Joussain","year":"2019","journal-title":"Toxins"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489224000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:04:03Z","timestamp":1726373043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489224000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":60,"alternative-id":["S1471489224000468"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2024.102476","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2024.102476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102476"}}